Objective: analyse the evolution in the prescription of cardiovascular disease preventive drugs (CVD) in a cohort of workers and study the effectiveness of this pharmacoprevention, as well as identify the determinants of these drugs. Methodology: follow-up study whose scope is the Aragón Workers Health Study (AWHS), a cohort study developed in the General Motors (GM) of Figueruelas, Zaragoza. Specific cohort monitoring information will be used, obtained from the Occupational Risk Prevention Service of GM and Miguel Servet University Hospital. This information will be complemented by information systems: Farmasalud (information on prescription drugs), Minimum Basic Data Set (CMBD), Electronic Hospital Emergency Clinical History (PCH) and Electronic Clinical History in Primary Care (IMO-AP), information on CVD morbidity will be obtained and deaths due to CVD will be obtained from the Mortality Registry. The study period is from 2010 to 2018 and will take place in different phases. First, the descriptive study of the frequency and evolution over time of the use of preventive CVD drugs, and of the frequency of cardiovascular events in the cohort will be carried out. Adherence and persistence to treatment, both for primary and secondary prevention, and adherence to secondary prevention guidelines will be studied. The effectiveness of the pharmacopreventive treatment on the control of intermediate results (analytical values and blood pressure) and endpoints (morbidity and mortality by CVD) will then be evaluated and the costs of pharmacoprevention analysed.